alpha-aminopyridine has been researched along with Acute Lymphoid Leukemia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Liu, J; Mi, RH; Wei, XD; Wei, XL; Yang, HP; Yin, QS; Zhang, LN | 1 |
| Dou, L; Guan, W; Jing, Y; Wang, M; Xiao, Y; Yu, L | 1 |
| Fang, JP; Han, XW; Huang, K; Li, XY; Xu, LH; Zhang, YT | 1 |
| Bian, S; Guo, Z; Kong, D; Li, Q; Li, Y; Lin, L; Lv, C; Sun, L; Wang, Y; Wu, M; Zhao, L; Zhou, J | 1 |
| Chen, K; Deng, M; Guo, X; Jiang, Z; Li, P; Shi, P; Xu, B; Zha, J; Zhang, L | 1 |
| Chang, S; Hou, T; Kong, X; Li, D; Li, Y; Pan, P; Sun, H; Xu, L; Zhu, F | 1 |
| Badura, S; Falkenburg, JH; Liebermann, M; Nijmeijer, BA; Ottmann, OG; Pfeifer, H; Ruthardt, M; Tesanovic, T; Wystub, S | 1 |
| Beyene, J; Danska, JS; Grandal, I; Guidos, CJ; Hitzler, JK; Kowalski, PE; Matei, IR; Minden, MD; Nutter, LM; Papp, E; Perova, T | 1 |
| Hubbard, SR; Silvennoinen, O | 1 |
| Andraos, R; Baffert, F; Chapuy, B; Christie, AL; Christodoulou, A; DeAngelo, DJ; Dölemeyer, A; Ebel, N; Eck, MJ; Gaul, C; Harris, M; Hofmann, F; Kopp, N; Kuo, F; Lane, AA; Layer, JV; Letai, A; Li, LS; Liu, H; Mandon, E; Montero, J; Murakami, M; Ng, SY; Radimerski, T; Rodig, SJ; Romanet, V; Ryan, JA; Sallan, SE; Silverman, LB; Steensma, D; Sterker, D; Stone, RM; Tivey, T; van Bodegom, D; van der Zwet, J; Vangrevelinghe, E; Wadleigh, M; Weinstock, DM; Wu, SC; Yoda, A; Zender, M | 1 |
| Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; DeBose, L; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Kornblau, S; Pemmaraju, N; Ragon, BK; Ravandi, F; Schneider, H; Wierda, W; Zeng, Z | 1 |
| Eckert, C; Einsiedel, HG; Fichtner, I; Henze, G; Kawan, L; Seeger, K; Witt, O | 1 |
1 trial(s) available for alpha-aminopyridine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
11 other study(ies) available for alpha-aminopyridine and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
[Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia].
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome | 2021 |
Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2020 |
[Preliminary Study of Chidamide Combined with Hematopoietic Stem Cell Transplantation in the Treatment of Childhood Acute T-Lymphoblastic Leukemia].
Topics: Aminopyridines; Benzamides; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Transplantation, Homologous | 2020 |
Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Mice; Mice, Inbred NOD; Mice, SCID; N-Myc Proto-Oncogene Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.
Topics: Adolescent; Adult; Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Damage; Female; Gene Deletion; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult | 2017 |
How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Topics: Allosteric Site; Aminopyridines; Benzimidazoles; Drug Resistance, Neoplasm; Entropy; Humans; Janus Kinase 2; Models, Molecular; Molecular Dynamics Simulation; Mutation; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Secondary; Pyrimidines | 2017 |
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Topics: Aminopyridines; Antineoplastic Agents; Drug Synergism; Everolimus; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphocytes; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Naphthyridines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Female; Humans; Intracellular Signaling Peptides and Proteins; Leukemia; Male; Mice; Mice, SCID; Morpholines; Mutation; Neoplasm Transplantation; Niacinamide; Oligonucleotide Array Sequence Analysis; Oxazines; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Recurrence; Signal Transduction; Spleen; Syk Kinase; Treatment Outcome | 2014 |
Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Dexamethasone; Drug Resistance, Neoplasm; Humans; Janus Kinase 2; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2015 |
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cytoprotection; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Humans; Janus Kinase 2; Mice; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Disease Models, Animal; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Heterologous | 2006 |